吉因加递表港交所

Group 1 - The core viewpoint of the article is that Geneplus Technology (Shaoxing) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, indicating its intention to go public [1] - Geneplus is recognized as a leading precision medicine company in China, integrating AI capabilities deeply into the biomarker value chain [1] - The company has developed a comprehensive capability from biomarker and target discovery, validation, product development to commercialization based on its self-developed multi-omics platform [1] Group 2 - Geneplus offers three main solutions targeting hospitals, pharmaceutical and biotechnology companies, and medical research institutions: precision diagnosis, drug development empowerment, and clinical research and translation [1] - The company is backed by joint sponsors, including CCB International and Minmetals Capital, for its listing process [1] - The shares are priced at RMB 1.00 per H share, with additional fees for commissions and transaction costs outlined in the prospectus [1]